Short answer
Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 contains Perspective Therapeutics’ corporate presentation, potentially relevant for updated strategy and investor messaging.
Perspective Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Exhibit 99.1 contains Perspective Therapeutics’ corporate presentation, potentially relevant for updated strategy and investor messaging
- Filing signed September 8, 2026 by CFO Joel Sendek
Item EX-99.1 · Exhibit EX-99.1
- Investor presentation outlines three independent clinical-stage programs, each targeting distinct cancers with data expected in 2026
- VMT-α-NET Phase 1/2a data cover 68 treated patients, supporting potential registration study at the current dose
- VMT01 showed preliminary antitumor activity at the 3.0 mCi dose in melanoma
- Pipeline targets a combined $45B+ solid-tumor market across neuroendocrine tumors, melanoma, and advanced solid tumors
- Integrated ²¹²Pb production and regional manufacturing support direct-to-hospital delivery and supply scalability
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Perspective Therapeutics, Inc. 8-K filings
Get the next CATX 8-K as it lands
Follow CATX for push alerts, or ask the research agent what this filing means.